About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Welcome to The Future of Diagnostic Tests

By: NewsUSA

(NewsUSA) - If you have a chronic or recurring infection, getting accurate results of diagnostic tests can make a big difference in your quality of care and quality of life. Patients with infections value the resolution that comes from accurate testing, diagnosis, and good treatment that MicroGenDX's Next-Generation DNA Sequencing (NGS) enables.

When a patient is infected, they will usually be prescribed an antibiotic or antifungal by their healthcare provider. These antimicrobials are often chosen based on culturing, growing the specimen in a petri dish. There are limitations to this 150-year-old technology that MicroGenDX is helping to solve.

MicroGenDX uses DNA sequencing technology to identify all bacteria and fungi in a sample from an infected patient, no growth required. NGS detects many microbes that cultures often miss. This provides a patient's physician with a more comprehensive result enabling appropriate and optimized therapy.

"Our mission at MicroGenDX is to improve clinical outcomes by offering clinicians and their patients the most informative and impactful microbial diagnostic tests that science can provide," says CEO Rick Martin. MicroGenDX makes a difference for patients like Kelsey, who struggled with a urinary tract infection so painful that it left her bedridden. When Kelsey finally received the correct antibiotic to treat her infection based on MicroGenDX test results, she was able to recover and return to a pain-free life.

"What makes MicroGenDX unique is our curated database of over 50,000 microbes, our improved turnaround time, our patient-friendly price point, and our clinical research data that strongly supports the clinical utility of Next-Generation Sequencing," Martin emphasizes.

Next-Generation Sequencing (NGS) is a technology that allows for more specific identification of disease-causing organisms than the traditional cultures and polymerase chain reaction (PCR) genetic tests used by many labs. Although the technology itself is not new, MicroGenDX, which has been in business for 12 years, has made NGS possible for use in an everyday clinical setting. In the past, NGS technology was expensive and time-consuming. Today, NGS is used by a variety of major companies and research institutions, including NASA, through MicroGenDX, and MicroGenDX is helping to open the door for the use of NGS in clinical medicine.

MicroGenDX provides results for diagnoses related to urinary tract infections (UTI), prostate infections, hip and knee infections, wound infections, sinus infections, lung infections and more. The company continues to conduct research to expand the evidence base for the technology, with more than 35 published clinical studies and more than 40 ongoing clinical trials.

MicroGenDX's NGS has a number of benefits over traditional culture and PCR labs:

- Accuracy. The MicroGenDX test matches patient samples against its microbial database of 50,000 species for maximum accuracy in the NGS results.

- Affordability. The MicroGenDX offers low rates for both qPCR and NGS to help clinicians and patients control costs without sacrificing quality.

- Speed. MicroGenDX has the quickest turn around time of any NGS provider on the market at 3-5 business days for most NGS samples.

- Variety. The MicroGenDX lab accepts a broad range of samples and can provide information on hard to culture and uncommon bacterial and fungal species, including Mycobacterium and Molds.

- Antibiotic Resistance: MicroGenDX recognizes the threat that antimicrobial resistant organisms present to current medicine and the over 35,000 deaths a year it causes. The use of NGS allows for targeted antibiotic treatment that helps combat the growing issue of antibiotic resistance. MicroGenDX also detects the presence of 17 antibiotic resistance genes allowing clinicians to avoid ineffective treatments.

Visit microgendx.com for more information about the company's services, and check them out on social media via Facebook, Twitter, and Instagram.

 

More News

View More
MarketBeat Week in Review – 10/06 - 10/10
Via MarketBeat
Topics Economy
Tickers ACHR AMD AMZN AVGO CELH CRWV
3 Heavily Shorted Stocks That Could Pop on Rate Cuts
Via MarketBeat
Topics Artificial Intelligence Economy
Tickers ETSY SMR SOUN
Broadcom Gets Second $420 Target as CPO Win Boosts Outlook
Via MarketBeat
Tickers AVGO META
PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can
Via MarketBeat
Tickers PEP
Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been
Via MarketBeat
Tickers DKNG
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.